Medite Cancer Diagnostics Inc (PK:MDIT)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 414 N Orleans St Ste 502
CHICAGO IL 60654-4498
Tel: N/A
Website: www.medite-group.com
IR: See website
<
Key People
Michaela Ott
Chief Operating Officer
Jeff Rencher
Chief Marketing and Business Development Officer
 
Business Overview
MEDITE Cancer Diagnostics, Inc. (MEDITE) is a medical technology company specialized in the development, manufacturing, and marketing of premium medical devices, consumables and molecular biomarkers for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. The Company also develops, manufactures, markets, and sells MEDITE branded products (instruments and consumables), in the areas of histology and cytology. The Company has a distribution network to over 80 countries and a range of products for anatomic pathology, histology and cytology laboratories available for sale. The Company's subsidiaries consist of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany and MEDITE Lab Solutions Inc.
Financial Overview
For the nine months ended 30 September 2018, Medite Cancer Diagnostics Inc revenues increased 27% to $6.2M. Net loss applicable to common stockholders decreased 35% to $2.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development, decrease of 40% to $705K (expense), Selling decrease of 7% to $3M (expense).
Employees: 5 as of Mar 27, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $6.62M as of Sep 30, 2018
Annual revenue (TTM): $8.13M as of Sep 30, 2018
EBITDA (TTM): -$3.73M as of Sep 30, 2018
Net annual income (TTM): -$5.42M as of Sep 30, 2018
Free cash flow (TTM): -$5.30M as of Sep 30, 2018
Net Debt Last Fiscal Year: $5.65M as of Sep 30, 2018
Shares outstanding: 86,723,700 as of Nov 10, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.